Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension.

Hypertension · 2020 · PMC7098434 · PMID 32063059

Europe PMC DOI

hedged sentence

0.1800

closest p · 3.6× alpha

0.1800

boldest claim

The sentences

did not reach statistical significanceP =0.18not close (p > 0.1)

Overall, BP reductions from baseline were greater in white patients ( P =0.0084 and P =0.037, for SiSBP and SiDBP, respectively) but did not reach statistical significance for female versus male patients ( P =0.18 and P =0.27, for SiSBP and SiDBP, respectively; Table S4a and S4b).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.